[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cognitive-function\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cognitive-function":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,36,0,25,[9,48,76,107,139,173,197,228,251,271,290,313,340,365,390,410,447,473,500,536,562,584,610,638,666],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100622819","a-clinical-trial-to-investigate-the-safety-and-efficacy-of-ap-brain-on-cognitive-function-at-varying-dosages-in-healthy-younger-adults-with-self-reported-attention-problems-100622819",false,"NCT07388576","A Clinical Trial to Investigate the Safety and Efficacy of AP-Brain on Cognitive Function at Varying Dosages in Healthy Younger Adults With Self-reported Attention Problems","A Randomized, Triple-blind, Placebo-controlled, Parallel, Proof-of-concept Clinical Trial to Investigate the Safety and Efficacy of AP-Brain on Cognitive Function at Varying Dosages in Healthy Younger Adults With Self-reported Attention Problems","Inclusion Criteria:\n\n1. Males and females 18-39 years of age, inclusive\n2. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening\n\n   Or,\n\n   Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:\n   * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)\n   * Double-barrier method\n   * Intrauterine devices\n   * Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)\n   * Vasectomy of partner at least 6 months prior to screening\n   * Abstinence and agrees to use contraception if planning on becoming sexually active\n3. Individuals with self-reported focus or attention problems, as determined by QI assessment of the Adult Attention Deficit Hyperactivity Disorder Self-Report Scale (Part A) (ASRS; version 1.1) (20)\n4. Agrees to avoid high sources of caffeine (e.g., supplements, tea, coffee, energy drinks), NSAIDs, and alcohol consumption for 24 hours prior to post-screening clinic visits\n5. Agrees to avoid first generation anti-allergy medication for 48 hours prior to post-screening clinic visits\n6. Agrees to avoid moderate-vigorous exercise 12 hours prior to post-screening clinic visits\n7. Agrees to avoid travel across two or more time zones two weeks prior to any study visit\n8. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study\n9. Willing and able to complete questionnaires, records, and diaries associated with the study and to complete all clinic visits\n10. Provided voluntary, written, informed consent to participate in the study\n11. Healthy as determined by medical history, laboratory results, and vital signs, as assessed by the QI\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study\n2. Allergy, sensitivity, or intolerance to the investigational product or placebo ingredients\n3. Clinical diagnosis and\u002For prescribed treatment for ADHD (See Section 7.3.1)\n4. Self-reported confirmation of any significant neuropsychological condition and\u002For cognitive impairment (e.g., autism spectrum disorder, schizophrenia, bipolar disorder, post-traumatic stress disorder, brain injury, neurodegenerative disease, infections, insomnia, depression, epileptic or other seizure-related disorders) that could interfere with study participation as assessed by the QI\n5. Self-reported color blindness\u002Fweakness as assessed by the QI\n6. Individuals who consume high caffeine daily or are addicted to caffeine at screening as assessed by the QI\n7. Current employment that calls for overnight shiftwork as assessed by the QI\n8. Unstable metabolic disease or chronic diseases as assessed by the QI\n9. Current or history of significant diseases of the gastrointestinal tract or conditions that result in malabsorption, as assessed by the QI\n10. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI (See Section 7.3.1)\n11. Type I diabetes\n12. Type II diabetes if on insulin treatment. Type II diabetics on stable medication for at least three months and an HbA1c of \\\u003C8.0% may be included after assessment by the QI on a case-by-case basis\n13. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis\n14. History of or current diagnosis with kidney, gallbladder (e.g., gallstones, bile duct obstruction), and\u002For liver diseases (e.g., reduced bile salts, SIBO) as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months\n15. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n16. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI\n17. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable\n18. Individuals with an autoimmune disease or are immune compromised as assessed by the QI\n19. Self-reported confirmation of a HIV-, Hepatitis B- and\u002For C-positive diagnosis as assessed by the QI\n20. Self-reported confirmation of blood\u002Fbleeding disorders as assessed by QI\n21. Use of medical cannabinoid products\n22. Chronic use of cannabinoid products (\\>2 times\u002Fweek). Occasional users will be required to washout and abstain for the duration of the study period\n23. Regular use of tobacco or nicotine products in the past six months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period\n24. Alcohol intake average of \\>2 standard drinks per day as assessed by the QI\n25. Alcohol or drug abuse within the last 12 months\n26. Current use of prescribed and\u002For OTC medications, supplements, and\u002For consumption of food\u002Fdrinks that may impact the efficacy and\u002For safety of the investigational product (Sections 7.3.1 and 7.3.2)\n27. Current or previous use of cognitive training programs or therapies, as assessed by the QI\n28. Clinically significant abnormal laboratory results at screening as assessed by the QI\n29. Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit\n30. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI\n31. Individuals who are cognitively impaired and\u002For unable to give informed consent\n32. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant",true,"ALL","18 Years","39 Years",{"count":22,"type":23},120,"ESTIMATED","INTERVENTIONAL",[26],"NA","The goal of this clinical trial is to investigate the safety and efficacy of AP-Brain on cognitive function at varying dosages in healthy younger adults with self-reported attention problems.\n\nThe main question it aims to answer is what Change from baseline to Day 56 between AP-Brain (1g, 3g, or 5g) and placebo in cognitive function, as assessed by the CNS VS Neurocognitive Index (NCI) score and complex attention.\n\nParticipants will be asked to consume AP-Brain at 1 g, 3 g, or 5g, or Placebo and asked to complete memory assessment questionnaires.",[29,30],"Cognition","Cognitive Function",[32,33,34],"memory","cognitive function","AP-Brain","RECRUITING","2026-06-19",{"date":38,"type":39},"2026-06-24","ACTUAL",{"date":41,"type":23},"2026-06",{"date":43,"type":23},"2026-11",{"name":45,"class":46},"Rousselot BVBA","INDUSTRY",2,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":17,"sex":18,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":24,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100641383","radicle-energy-vbmtm-a-study-assessing-the-impact-of-health-and-wellness-products-on-fatigue-and-related-health-outcomes-100641383","NCT07653724","Radicle Energy VBMTM: A Study Assessing the Impact of Health and Wellness Products on Fatigue and Related Health Outcomes","Radicle Energy VBMTM: A Randomized, Double-Blind, Placebo-Controlled Study Assessing the Impact of Health and Wellness Products on Fatigue and Related Health Outcomes","Participants must meet all the following criteria:\n\n* Adults, at least 21 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities\n\n  * Assigned sex at birth will determine sex-specific recruitment and PROs (male vs female) employed, when needed\n* Resides in the United States\n* Has the opportunity for at least 30% improvement in their primary health outcome\n* Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study\n\n3.2 Exclusion\n\nIndividuals who report any of the following during screening may be excluded from participation:\n\n* Report being pregnant, trying to become pregnant, or breastfeeding\n* Unable to provide a valid US shipping address and mobile phone number\n* Reports current enrollment in another clinical trial\n* Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)\n* Unable to read and understand English at a 7th grade level\n* Reports a current and\u002For recent (up to 3 months ago) major illness and\u002For surgery that poses a known, significant safety risk.\n* Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and\u002For a significant safety risk with any of the study product ingredients.\n\n  * NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure\n* Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients.\n\n  * Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products\n* Reports current use of caffeine-alternative products\n* Reports consuming 3 or more caffeinated beverages a day\n* Lack of reliable daily access to the internet","21 Years","105 Years",{"count":58,"type":23},550,[26],"Radicle Energy VBMTM: A randomized, double-blind, placebo- controlled direct-to-consumer study assessing the impact of health and wellness products on fatigue and related health outcomes.",[62,30,63,64],"Fatigue","Global Mental Health","Sleep Disturbance","NOT_YET_RECRUITING","2026-06-12",{"date":68,"type":39},"2026-06-17",{"date":70,"type":23},"2026-06-25",{"date":72,"type":23},"2027-06-25",{"name":74,"class":46},"Radicle Science",1,{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":17,"sex":84,"minAge":19,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":24,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":75},"100482574","exploring-virtual-reality-adventure-training-exergaming-100482574","NCT05563805","Exploring Virtual Reality Adventure Training Exergaming","Exploring Virtual Reality Adventure Training Exergaming (V-RATE) on Veterans' Health Outcomes","V-RATE","Inclusion Criteria:\n\n1. Are between the ages of 18 and 45\n2. Identify as a U.S. military veteran\n\n4\\. Normal vision (no colorblindness)\n\nExclusion Criteria:\n\n1. Unable to walk independently (e.g., use of any mobility assistive device such as brace, wheelchair, cane, crutch, walker, knee scooter)\n2. Self-reported joint problem that limits mobility (e.g., arthritis or other condition that would prevent participation) or ongoing orthopedic injury\n3. Self-reported pregnancy or suspicion of pregnancy\n4. Self-reported motor disorder or impaired sense of motion or balance (such as Parkinsonism)\n5. Self-reported color blindness\n6. Self-reported neurological or cognitive disorder (e.g., TBI, history of seizure)\n7. Self-reported cardiac surgery or any ongoing cardiovascular issues preventing participation or physical activity.","FEMALE","45 Years",{"count":87,"type":23},40,[26],"The current project aims to design and implement an 8-week Virtual Reality Adventure Therapy Exergaming (V-RATE) intervention focused on women veterans. A randomized controlled trial using a repeated measure design with a 1-month follow-up assessment will be employed to examine effects on physical and mental health outcomes.",[91,92,93,30,94,95,96],"Physical Activity","Sedentary Behavior","Depression","Post Traumatic Stress Disorder","Quality of Life","Anxiety","2026-05-27",{"date":99,"type":39},"2026-06-01",{"date":101,"type":39},"2022-09-07",{"date":103,"type":23},"2027-08-31",{"name":105,"class":106},"The University of Texas at Arlington","OTHER",{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":17,"sex":18,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":24,"phases":118,"briefSummary":119,"conditions":120,"keywords":127,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":137,"locationsCount":75},"100637581","effect-of-hot-spring-therapy-on-cognitive-function-recovery-during-altitude-training-100637581","NCT07608913","Effect of Hot Spring Therapy on Cognitive Function Recovery During Altitude Training","A Randomized Controlled Trial Investigating the Effects of Balneotherapy on Cognitive Performance, Cerebral Hemodynamics, and Exercise Capacity in Healthy Adults Undergoing Simulated Altitude Training","Inclusion Criteria:\n\n* Male or female aged 11-17 years- Regular endurance training (≥3 sessions\u002Fweek) for ≥2 years\n* No history of altitude exposure \\>2000m in the past 3 months\n* No contraindications to hot water immersion (e.g., uncontrolled hypertension, severe cardiovascular disease, open wounds, pregnancy)\n* Ability to provide written informed consent\n* Willingness to abstain from other recovery modalities (e.g., massage, cryotherapy, compression garments) during the study period\n* No color blindness or uncorrected visual impairment that would affect Stroop test performance\n\nExclusion Criteria:\n\n* History of cardiovascular, respiratory, renal, or endocrine disorders\n* Current use of medications affecting autonomic function or cognition (e.g., beta-blockers, anticholinergics, stimulants, sedatives)\n* History of syncope, heat intolerance, or neurological disorders\n* Acute musculoskeletal injury within the past 6 months- Regular use of sauna, hot tub, or spa within the past month- Pregnancy or breastfeeding (for female participants)\n* Shift work or trans-meridian travel within 2 weeks prior to baseline assessment- Alcohol consumption \\>14 units\u002Fweek or smoking\n* History of traumatic brain injury, stroke, or psychiatric disorders","11 Years","17 Years",{"count":117,"type":23},27,[26],"This randomized controlled trial aims to investigate the effects of hot spring bath therapy on cognitive function recovery, cerebral hemodynamics, and athletic performance in athletes undergoing altitude training. Participants will be randomly assigned to either a hot spring intervention group, a hot water control group, or a blank control group. The hot spring intervention group receives hot spring baths (38°C, 20 minutes) combined with altitude training; the hot water control group receives hot water baths (38°C, 20 minutes) combined with altitude training; and the blank control group receives standard recovery procedures combined with altitude training. Primary outcome measures include cognitive performance assessments (Stroop test, psychomotor vigilance test) and cerebral hemodynamic indicators (functional near-infrared spectroscopy, transcranial Doppler ultrasound). Secondary outcomes included exercise capacity (maximal oxygen uptake, triathlon performance, 500-meter test), blood lactate, and hematological parameters (white blood cells, neutrophils, platelets). These findings may provide evidence for non-pharmacological interventions to enhance cognitive recovery and brain adaptation during altitude training.",[121,30,122,123,124,125,126],"Altitude Training Adaptation","Cerebral Hemodynamics","Exercise Performance","Hydrotherapy","Balneotherapy","Hypoxia",[128,29,129,130,124,131],"Altitude Sickness","Cerebrovascular Circulation","Physical Performance","Hot Springs","2026-05-19",{"date":97,"type":39},{"date":135,"type":23},"2026-05-25",{"date":70,"type":23},{"name":138,"class":106},"Macao Polytechnic University",{"id":140,"slug":141,"hasResults":12,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":24,"phases":149,"briefSummary":150,"conditions":151,"keywords":159,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":75},"100640010","mobile-dual-task-brain-and-balance-intervention-for-concussion-recovery-100640010","NCT07599475","Mobile Dual-Task Brain and Balance Intervention for Concussion Recovery","Boosting Brain and Balance: A Mobile Dual-Task Intervention for Athletes With Concussion and Mild Traumatic Brain Injury (mTBI)","Inclusion Criteria:\n\n* Adults aged 18 to 40 years\n* Self-reported history of sports-related concussion (SRC) or mild traumatic brain injury (mTBI) within the past 3 to 12 months\n* Meets criteria for mTBI based on a standardized screening method (e.g., Ohio State University TBI Identification Method)\n* Able to safely participate in light physical activity (e.g., walking) and simple cognitive tasks based on self-report and observational screening by the research team\n* Able to read and understand English (if applicable for study materials)\n* Able to provide informed consent\n* Has access to and is able to use a smartphone or mobile device to complete daily app-based activities\n\nExclusion Criteria:\n\n* Age younger than 18 years or older than 40 years\n* History of moderate or severe traumatic brain injury\n* Concussion or mTBI occurring less than 3 months or more than 12 months prior to enrollment\n* Self-reported active medical disease or history of neurological or psychiatric conditions unrelated to concussion\n* Self-reported other medical conditions that would limit safe participation in light physical activity (e.g., walking or balance tasks)\n* Currently on prescribed medications that may significantly affect cognitive function, balance, neurological function, or safe participation in light physical activity\n* Inability to use a smartphone or mobile device required for study participation\n* Inability to read or understand English (as study materials and the mobile application are currently available only in English)","40 Years",{"count":148,"type":23},20,[26],"This research study examines recovery after a sports-related concussion or mild head injury. Many athletes experience lingering problems with thinking, balance, and mood months after a concussion.\n\nWe are testing a new home-based program called BraW-Day™ (Brain \\& Walk Exercise Every Day). This 14-day program uses a mobile app on your smartphone and combines simple brain exercises (like counting backwards) with walking exercises. The idea is that doing these tasks together may help your brain and body recover more effectively.\n\nWhat You'll Do:\n\n* Two in-person visits at UNLV (baseline and after 14 days) for assessments\n* Daily 15-minute exercises at home using the BraW-Day app\n* Provide a small saliva sample for biomarker testing\n* Complete brief questionnaires about your symptoms and health\n\nPotential Benefits:\n\nYou may experience improvements in thinking, balance, or mood. Even if you don't benefit directly, your participation will help researchers understand how to better support athletes recovering from concussion.\n\nWho Can Join:\n\n* Ages 18-40\n* Had a sports-related concussion or mild head injury within the past 3-12 months\n* Have a smartphone and can safely do light walking and simple tasks\n\nThis study is registered at ClinicalTrials.gov and approved by the UNLV Institutional Review Board to protect your safety and rights.",[152,153,154,155,156,157,158,30],"Mild Traumatic Brain Injury (mTBI)","Sports-related Concussion","Heart Rate Variability (HRV)","Walking","Oculomotor","Saliva","Exosomal microRNA",[160,161,162,163],"dual-task","mild traumatic brain injury (mTBI)","sports-related concussion","BraW-Day","2026-05-14",{"date":166,"type":39},"2026-05-20",{"date":168,"type":23},"2026-05-15",{"date":170,"type":23},"2027-04-30",{"name":172,"class":106},"Hyunhwa Lee",{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":17,"sex":18,"minAge":180,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":183,"phases":4,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":75},"100639707","gait-and-cognitive-function-in-relation-to-foot-arch-structure-in-older-adults-100639707","NCT07582367","Gait and Cognitive Function in Relation to Foot Arch Structure in Older Adults","Relationship Between Foot Arch Structure, Spatiotemporal Gait Parameters, and Cognitive Function in Older Adults","Inclusion Criteria:\n\n* Aged 65 years or older\n* Able to walk independently for at least 10 meters without assistive devices\n* Able to understand study procedures and provide informed consent\n* Having sufficient cognitive and physical capacity to comply with the assessment protocol\n\nExclusion Criteria:\n\n* Diagnosed neurological disorders affecting gait and motor control (e.g., stroke, Parkinson's disease, multiple sclerosis)\n* Diagnosed dementia or Alzheimer's disease, or Mini-Mental State Examination (MMSE) score below 24\n* Severe visual or hearing impairment that cannot be corrected and may affect reaction time testing\n* History of major lower extremity or spinal surgery within the last 6 months Severe musculoskeletal conditions affecting gait (e.g., advanced osteoarthritis, severe pain, active inflammation, open wounds, or recent fractures in the lower extremity)\n* Presence of severe balance disorders (e.g., vertigo)","65 Years",{"count":182,"type":23},50,"OBSERVATIONAL","This study aims to investigate the relationship between foot arch structure and spatiotemporal gait parameters and cognitive function in older adults. Foot arch integrity will be assessed using the Navicular Drop Test, and gait performance will be evaluated using the 10-Meter Walk Test. Cognitive-motor interaction will be examined through lower extremity reaction time using a light-based system. The study is designed as an observational cross-sectional analysis.",[186,187,30],"Gait","Foot Biomechanics","2026-05-07",{"date":190,"type":39},"2026-05-12",{"date":192,"type":39},"2026-04-15",{"date":194,"type":23},"2026-11-08",{"name":196,"class":106},"Balikesir University",{"id":198,"slug":199,"hasResults":12,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":17,"sex":18,"minAge":180,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":24,"phases":207,"briefSummary":209,"conditions":210,"keywords":217,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":221,"startDateStruct":222,"completionDateStruct":223,"leadSponsor":225,"locationsCount":227},"100638808","phase-4-long-term-follow-up-of-dexmedetomidine-esketamine-and-tdcs-for-neurocognitive-complications-after-surgery-100638808","NCT07576543","Long-term Follow-up of Dexmedetomidine-esketamine and tDCS for Neurocognitive Complications After Surgery","Long-term Follow-up of Perioperative Dexmedetomidine-esketamine Combination and Transcranial Direct Current Stimulation for Prevention of Neurocognitive Complications in Older Patients After Non-cardiac Surgery","Inclusion Criteria:\n\n* Aged 65 to 90 years;\n* Preoperative Mini-Mental State Examination (MMSE) score \\\u003C 27 points, indicating possible cognitive impairment ranging from mild to moderate;\n* Scheduled to undergo elective non-cardiac, non-neurosurgical surgery under general anesthesia, with an expected surgical duration \\> 1 hour;\n* Required patient-controlled intravenous analgesia (PCIA) after surgery.\n\nExclusion Criteria:\n\n* Preoperative inability to communicate due to coma, severe dementia, endstage disease, or language impairment;\n* History of schizophrenia, epilepsy, Parkinson's disease, brain trauma\u002Fsurgery, or myasthenia gravis;\n* Presence of metal implants in the intracranial or cervical region (such as cochlear implants, aneurysm clips, deep brain stimulation electrodes), or skin damage or severe skin disease on the head;\n* Severe cardiac dysfunction (left ventricular ejection fraction \\\u003C 30%), comorbid with sick sinus syndrome, severe bradycardia (heart rate \\\u003C 50 bpm), or second-degree or higher atrioventricular block, or implantation of a cardiac pacemaker;\n* Uncontrolled hyperthyroidism or pheochromocytoma;\n* Severe liver dysfunction (Child-Pugh class C), severe renal dysfunction (requiring dialysis), or ASA classification ≥ IV;\n* Allergy to dexmedetomidine or esketamine;\n* Participation in other clinical studies within the past 3 months;\n* Other conditions that are deemed unsuitable for study participation.","90 Years",{"count":206,"type":23},1160,[208],"PHASE4","Neurocognitive complications, mainly delirium and neurocognitive disorders, are common cerebral complications in older patients after surgery and associated with worse long-term outcomes. An ongoing 2×2 factorial trial conducted by the investigators plan to test the effects of perioperative dexmedetomidine-esketamine combination and transcranial direct current stimulation (tDCS) on postoperative neurocognitive complications in older patients. This long-term follow-up of the ongoing trial aims to investigate the effects of perioperative dexmedetomidine-esketamine combination and tDCS on long-term outcomes in older patients after noncardiac surgery.",[211,212,213,214,215,30,216],"Older Patients","Surgery","Dexmedetomidine","Esketamine","Transcranial Direct Current Stimulation","Survival",[218,212,213,214,219,220,216],"Older patients","Transcranial direct current stimulation","Cognitive function",{"date":190,"type":39},{"date":41,"type":23},{"date":224,"type":23},"2031-06",{"name":226,"class":106},"Peking University First Hospital",6,{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":17,"sex":84,"minAge":235,"maxAge":180,"enrollmentInfo":236,"targetDuration":4,"studyType":183,"phases":4,"briefSummary":237,"conditions":238,"keywords":240,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":75},"100385308","brain-health-in-breast-cancer-survivors-100385308","NCT04297020","Brain Health in Breast Cancer Survivors","Brain Health in Breast Cancer Survivors: Interaction of Menopause and Endocrine Therapy","Inclusion Criteria:\n\n* Age 35-65\n* Fluent in English\n* Adequate vision\u002Fhearing to complete testing\n\nExclusion Criteria:\n\n* History of major or mild neurocognitive disorder or dementia\n* Diagnosis of major neurological condition (e.g., epilepsy, Parkinson's Disease, stroke)\n* Diagnosis of a major psychiatric disorder (e.g., bipolar disorder, schizophrenia)\n* Untreated\u002Funstable unipolar depression or anxiety\n* Prior history of cancer or chemotherapy (for controls, any history)\n* History of a learning disorder\n* History of head injury with loss of consciousness \\>20 minutes\n* History of salpingo-oophorectomy or hysterectomy\n* A cardiac pacemaker\n* Implanted electronic device\n* Claustrophobia\n* Currently pregnant\n* Orbital metal implant or other metallic foreign bodies\n\nAdditional exclusion criteria for controls: current use of a contraceptive agent that interferes with endogenous hormonal fluctuation (e.g., oral contraceptive pill) or precludes determination of menstrual pattern (e.g., hormonally secreting intrauterine device), or current treatment with systemic estrogen replacement therapy.","35 Years",{"count":22,"type":23},"Endocrine therapy (ET) is widely used to treat hormone receptor positive breast cancer and prevent recurrence by downregulating estrogen function. However, ETs readily cross the blood brain barrier and interfere with the action of estrogen in the brain. Estrogen supports cognition and menopausal status is closely linked to cognitive health in women. This has raised concern that anti-estrogen ETs may affect cognition and brain health in breast cancer survivors. However, evidence across existing studies is inconsistent and these effects remain poorly understood. The incomplete understanding of the effects of ET are likely due to limitations of earlier studies - namely, the under-appreciation of the role of menopausal status and insensitivity of standard cognitive measures. This research project will address these earlier limitations by specifically comparing ET effects by menopausal status, and using highly sensitive, task-related functional magnetic resonance imaging (fMRI) measures to assess the effects of ET on brain function.",[239,30],"Cognitive Impairment",[241,242],"Breast cancer","endocrine therapy",{"date":244,"type":39},"2026-05-11",{"date":246,"type":39},"2020-03-11",{"date":248,"type":23},"2028-03-15",{"name":250,"class":106},"Jonsson Comprehensive Cancer Center",{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":17,"sex":84,"minAge":146,"maxAge":56,"enrollmentInfo":258,"targetDuration":4,"studyType":24,"phases":260,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":75},"100635101","radicle-revive-a-study-assessing-the-impact-of-health-and-wellness-products-on-menopausal-related-health-issues-associated-health-outcomes-and-related-health-outcomes-100635101","NCT07548307","Radicle Revive™: A Study Assessing the Impact of Health and Wellness Products on Menopausal-Related Health Issues Associated Health Outcomes and Related Health Outcomes","Radicle Revive™: A Randomized, Double-Blind, Placebo-Controlled Direct-to-Consumer Study Assessing the Impact of Health and Wellness Products on Menopausal-Related Health Issues Associated Health Outcomes and Related Health Outcomes","Inclusion\n\nParticipants must meet all the following criteria:\n\n* Adults, at least 40 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities\n* Assigned sex at birth will determine sex-specific recruitment\n* Resides in the United States\n* Has the opportunity for at least 30% improvement in their primary health outcome\n* Peri or Post Menopausal women who have been experiencing hot flashes for the past 3 months or longer\n* Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study\n\nExclusion\n\nIndividuals who report any of the following during screening may be excluded from participation:\n\n* Report being pregnant, trying to become pregnant, or breastfeeding\n* Unable to provide a valid US shipping address and mobile phone number\n* Reports current enrollment in another clinical trial\n* Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)\n* Unable to read and understand English at a 7th grade level\n* Reports a current and\u002For recent (up to 3 months ago) major illness and\u002For surgery that poses a known, significant safety risk.\n* Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and\u002For a significant safety risk with any of the study product ingredients.\n* NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure\n* Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients.\n* Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products\n* Reports current use of the primary ingredient(s) and\u002For similar product(s) to the active study product(s) that may limit the effects of the study products and\u002For pose a safety risk\n* Lack of reliable daily access to the internet\n* Currently taking a HRT medication\n* Pre-Menopausal women",{"count":259,"type":23},990,[26],"Radicle Revive™: A randomized, double-blind, placebo-controlled study assessing the impact of health and wellness products on menopausal-related health issues associated health outcomes.",[30],"2026-04-17",{"date":265,"type":39},"2026-04-23",{"date":267,"type":39},"2026-04-09",{"date":269,"type":23},"2027-04-07",{"name":74,"class":46},{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":17,"sex":18,"minAge":235,"maxAge":278,"enrollmentInfo":279,"targetDuration":4,"studyType":24,"phases":280,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":75},"100619251","radicle-clarity-dsttm-a-study-assessing-the-impact-of-health-and-wellness-products-on-mental-clarity-and-related-health-outcomes-100619251","NCT07342192","Radicle Clarity DSTTM: A Study Assessing the Impact of Health and Wellness Products on Mental Clarity and Related Health Outcomes","Radicle Clarity DSTTM: A Randomized, Double-Blind, Placebo-Controlled Direct-to-Consumer Study Assessing the Impact of Health and Wellness Products on Mental Clarity and Related Health Outcomes","Inclusion\n\nParticipants must meet all the following criteria:\n\n* Adults, 35-60 years of age (inclusive) at the time of electronic consent, inclusive of all ethnicities, races, and gender identities\n\n  * Assigned sex at birth will determine sex-specific recruitment and surveys (male vs female) employed, when needed\n* Resides in the United States\n* Has the opportunity for at least 30% improvement in their primary health outcome\n* Expresses a willingness to take a study product and not know the product identity(active or placebo) until the end of the study\n\nExclusion\n\nIndividuals who report any of the following during screening may be excluded from participation:\n\n* Report being pregnant, trying to become pregnant, or breastfeeding\n* Unable to provide a valid US shipping address and mobile phone number\n* Reports current enrollment in another clinical trial\n* Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)\n* Unable to read and understand English at a 7th grade level\n* Reports a current and\u002For recent (up to 3 months ago) major illness and\u002For surgery that poses a known, significant safety risk.\n* Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and\u002For a significant safety risk with any of the study product ingredients.\n\n  * NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure\n* Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients.\n\n  * Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products\n* Reports current use of the primary ingredient(s) and\u002For similar product(s) to the active study product(s) that may limit the effects of the study products and\u002For pose a safety risk\n* Lack of reliable daily access to the internet\n* Reports current use of prescription medication(s) for cognitive enhancement\n* Reports current regular cannabis use","60 Years",{"count":259,"type":23},[26],"Radicle Clarity DSTTM: A randomized, double-blind, placebo-controlled direct-to-consumer study assessing the impact of health and wellness products on mental clarity and related health outcomes.",[30],{"date":284,"type":39},"2026-04-21",{"date":286,"type":39},"2026-01-22",{"date":288,"type":23},"2027-01-21",{"name":74,"class":46},{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":180,"enrollmentInfo":296,"targetDuration":4,"studyType":24,"phases":298,"briefSummary":299,"conditions":300,"keywords":301,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":75},"100482025","brain-stimulation-effects-on-cognitive-task-performance-100482025","NCT05556655","Brain Stimulation Effects on Cognitive Task Performance","Inclusion Criteria:\n\n* Right-handed\n* Fluent in English\n\nExclusion Criteria:\n\n* History of seizures or epilepsy\n* Family history of epilepsy\n* Significant medical or neurological diagnoses\n* History of common headache or migraine\n* History of common or recent syncope\n* History of moderate\u002Fsevere, multiple mild, or past 12 months head injury\n* History of psychiatric, psychological, or neurodevelopmental disorder\n* History of alcohol or recreational drug abuse or dependence\n* Current visual or hearing difficulties that interfere with cognitive testing\n* History of cochlear implants\n* Current pregnancy\n* History of metal in the head or neck (except braces and fillings)\n* Current non-removable piercings in the neck or head\n* History of implanted neurostimulator\n* History of cardiac pacemaker or intracardiac lines\n* History of medication infusion device\n* Current use of medications that increase the excitability of the brain\n* History of problems with TMS or MRI procedures\n* History of EEG for suspected epilepsy\n* Alcohol or recreational drug use in the 48 hours prior to TMS\n* Inadequate sleep in the 48 hours prior to TMS\n* Headache or feeling faint in the 24 hours prior to TMS.",{"count":297,"type":23},100,[26],"The purpose of this study is to determine optimal task design parameters for the measurement of transcranial magnetic stimulation (TMS) effects on cognition.",[30],[302,303],"Transcranial Magnetic Stimulation","TMS","2026-04-02",{"date":306,"type":39},"2026-04-08",{"date":308,"type":39},"2023-04-20",{"date":310,"type":23},"2028-01-01",{"name":312,"class":106},"Colorado State University",{"id":314,"slug":315,"hasResults":12,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":18,"minAge":278,"maxAge":320,"enrollmentInfo":321,"targetDuration":4,"studyType":24,"phases":323,"briefSummary":324,"conditions":325,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":75},"100619829","imst-for-dementia-risk-reduction-100619829","NCT07349706","IMST for Dementia Risk Reduction","Randomized Controlled Pilot Trial of Inspiratory Muscle Strength Training (IMST) to Reduce Dementia Risk in Older Adults","Inclusion Criteria:\n\n* Ages 60-80\n* Converted telephone MoCA total score≥18\n* Presence of at least one dementia risk factor (e.g., MCI or subjective cognitive decline, hypertension \\[SBP \\>130 mmHg or on medication\\], sedentary lifestyle \\[\\\u003C150 min\u002Fweek\\], family history of dementia or self-reported APOE ε4 carrier, or mild sleep-disordered breathing; CAIDE total score \\[\\>5\\]\n* Capable of independently completing or requiring minimal assistance with inspiratory muscle strength training (IMST)\n* Willing to adhere to the IMST protocol (approximately 5-10 minutes per day for 8 weeks)\n* Optional inclusion of inspiratory muscle weakness (MIP \\\u003C80 cmH₂O for men, \\\u003C70 cmH₂O for women) will also be assessed.\n\nExclusion Criteria:\n\n* tMoCA \\\u003C18, or diagnosis of neurodegenerative illness at the discretion of principal investigator (except MCI)\n* Current evidence of any major psychiatric disorder including psychosis (at the discretion of principal investigator), bipolar disorder, severe major depression (PHQ-9 \\> 20)\n* Unstable cardiovascular or pulmonary disease\n* Recent respiratory therapy or major medication changes\n* Self-reported severe untreated or unstable obstructive sleep apnea (OSA)\n* Recent start (within the past month) of CPAP or BiPAP, or recent use of inspiratory muscle training\n* Lung and eardrum injuries\n* Non-English speaking\n* Participants with a pacemaker or other medical implants containing magnets or electronics will be noted and excluded from body composition analyses.","80 Years",{"count":322,"type":23},30,[26],"Using a 2-arm, RCT approach, the primary goal of the study is to evaluate the feasibility and preliminary efficacy of Inspiratory Muscle Strength Training (IMST) as a non-pharmacologic intervention to reduce cardiovascular and cognitive risks in older adults. Next, investigators will examine secondary effects of IMST on mood, sleep quality, systemic inflammation, and physical\u002Fmotor function. Finally, investigators will assess participant adherence and acceptability ratings of using an 8-week home-based IMST protocol in a diverse older adult sample.",[326,327,328,96,329,330,30],"Systolic Blood Pressure","Blood Pressure","Depression - Major Depressive Disorder","Sleep Quality","Physical Function","2026-03-24",{"date":333,"type":39},"2026-03-27",{"date":335,"type":39},"2025-11-17",{"date":337,"type":23},"2026-12",{"name":339,"class":106},"Florida State University",{"id":341,"slug":342,"hasResults":12,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":278,"enrollmentInfo":347,"targetDuration":4,"studyType":24,"phases":348,"briefSummary":349,"conditions":350,"keywords":352,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":75},"100593252","a-clinical-trial-to-assess-the-efficacy-of-a-single-dose-of-alphawave-l-theanine-on-cognitive-function-in-healthy-adults-with-moderate-stress-100593252","NCT07004023","A Clinical Trial to Assess the Efficacy of a Single-dose of AlphaWave® L-Theanine on Cognitive Function in Healthy Adults With Moderate Stress","A Randomized, Triple-blind, Placebo Controlled, Cross-over Clinical Trial to Assess the Efficacy of a Single Dose of AlphaWave® L-Theanine on Cognitive Function in Healthy Adults With Moderate Stress","Inclusion Criteria:\n\n1. Males and females 18 to 60 years of age, inclusive\n2. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening\n\n   Or,\n\n   Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:\n   * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)\n   * Double-barrier method\n   * Intrauterine devices\n   * Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s)\n   * Vasectomy of partner at least 6 months prior to screening\n   * Abstinence and agrees to use contraception if planning on becoming sexually active during the study\n3. Individuals with moderate stress as determined by a score of 14 to 26 on the Perceived Stress Scale\n4. Have a regular sleep-wake cycle with a bedtime between 9:00 pm and 12:00 am and receive between 7 and 9 hours of sleep for at least 3 weeks prior to baseline\n5. Agrees to avoid caffeine (e.g., tea, coffee, energy drinks) for 12 h prior to post-screening clinic study visits\n6. Agrees to avoid alcohol consumption and vigorous physical activity for 24 h prior to post-screening clinic study visits\n7. Agrees to avoid first generation anti-allergy medication for 48 h prior to post-screening clinic study visits\n8. Willingness to complete assessments and diaries associated with the study and to complete all visits\n9. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study\n10. Provided voluntary, written, informed consent to participate in the study\n11. Healthy as determined by medical history as assessed by the Qualified Investigator (QI)\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study\n2. Allergy, sensitivity, intolerance, or dietary restriction preventing consumption of investigational product or placebo ingredients\n3. Self-reported confirmation of any significant neuropsychological condition and\u002For cognitive impairment (e.g., Schizophrenia, bipolar disorder, post-traumatic stress disorder, brain injury, stroke, neurodegenerative disease, infections, insomnia, depression, epileptic or other seizure-related disorders) that could interfere with study participation as assessed by the QI\n4. Self-reported color blindness\u002Fweakness as assessed by the QI\n5. Current employment that calls for rotating shift work or shift work that will disrupt normal circadian rhythm in the last three weeks as assessed by the QI\n6. Unstable metabolic disease or chronic diseases as assessed by the QI\n7. Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI\n8. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n9. Type I or Type II diabetes\n10. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis\n11. History of or current diagnosis with kidney and\u002For liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months\n12. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n13. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI\n14. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable\n15. Individuals with an autoimmune disease or are immune compromised as assessed by the QI\n16. Use of medical cannabinoid products as assessed by the QI\n17. Chronic use of cannabinoid products (\\>2 times\u002Fweek). Occasional users will be required to washout and abstain for the duration of the study period\n18. Regular use of tobacco or nicotine products in the past six months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period\n19. Alcohol intake average of \\>2 standard drinks per day as assessed by the QI\n20. Alcohol or drug abuse within the last 12 months\n21. Current use of prescribed and\u002For over-the-counter (OTC) medications, supplements, and\u002For consumption of food\u002Fdrinks that may impact the efficacy and\u002For safety of the investigational product (Section 7.3)\n22. Participation in other clinical research studies 30 days prior to baseline as assessed by the QI\n23. Individuals who are cognitively impaired and\u002For who are unable to give informed consent\n24. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant",{"count":87,"type":23},[26],"The goal of this clinical trial is to to assess the efficacy AlphaWave® L-Theanine on mental acuity\u002Fcognitive function and stress relief in healthy adults with moderate stress. The main question it aims to answer is:\n\nIs there a difference in change in mental acuity from pre- to post-dose between AlphaWave® L-Theanine and placebo?\n\nParticipants will asked to provided a single dose of one capsule of a single dose of one capsule of AlphaWave® L-Theanine or one placebo capsule with 250 ml of room temperature water, and asked to complete tasks to assess cognitive function.",[30,351],"Moderate Stress",[353,351,354,355],"Perceived Stress","AlphaWave L-Theanine","L-theanine","2026-03-11",{"date":358,"type":39},"2026-03-12",{"date":360,"type":39},"2025-11-29",{"date":362,"type":23},"2026-03",{"name":364,"class":106},"Ethical Naturals, Inc.",{"id":366,"slug":367,"hasResults":12,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":4,"eligibilityCriteria":371,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":180,"enrollmentInfo":372,"targetDuration":4,"studyType":183,"phases":4,"briefSummary":373,"conditions":374,"keywords":377,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":75},"100561340","investigation-of-motor-imagery-ability-body-awareness-and-cognitive-functions-in-type-2-diabetes-mellitus-100561340","NCT06588894","Investigation of Motor Imagery Ability, Body Awareness and Cognitive Functions in Type 2 Diabetes Mellitus","Relationship Between Motor Imagery Ability, Body Awareness and Cognitive Functions in Individuals With Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n* Being a type 2 DM patient between the ages of 18-65 for at least 5 years,\n* Being willing to participate in the study,\n* Not having any vision, hearing or speech problems that would prevent the tests from being performed.\n\nExclusion Criteria:\n\n* Having previous experience with Motor Imagery techniques or training,\n* Having any orthopedic problems that prevent walking,\n* Having a history of neurological disease,\n* People who are receiving any medication that affects the central nervous system will not be included in the study.",{"count":297,"type":23},"The aim of this study is to examine the relationship between motor imagery skills, body awareness and cognitive functions in individuals with Type 2 Diabetes mellitus.",[375,30,376],"Type 2 Diabetes Mellitus (T2DM)","Motor İmagery Ability",[378,379,380],"cognitive functions","motor imagery ability","type 2 diabetes mellitus","2026-03-09",{"date":383,"type":39},"2026-03-10",{"date":385,"type":39},"2024-10-14",{"date":387,"type":23},"2026-12-10",{"name":389,"class":106},"Kutahya Health Sciences University",{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":17,"sex":18,"minAge":55,"maxAge":85,"enrollmentInfo":397,"targetDuration":4,"studyType":24,"phases":399,"briefSummary":400,"conditions":401,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":75},"100622695","radicle-clarity-cnm-a-study-assessing-the-impact-of-health-and-wellness-products-on-cognitive-function-and-related-health-outcomes-among-e-gamers-100622695","NCT07386964","Radicle Clarity CNM™: A Study Assessing the Impact of Health and Wellness Products on Cognitive Function and Related Health Outcomes Among E-Gamers","Radicle Clarity CNM™: A Randomized, Double-Blind, Placebo-Controlled Direct-to-Consumer Study Assessing the Impact of Health and Wellness Products on Cognitive Function and Related Health Outcomes Among E-Gamers","Inclusion\n\nParticipants must meet all the following criteria:\n\n* Adults, aged 21 - 45 years at the time of electronic consent, inclusive of all ethnicities, races, and gender identities\n\n  * Assigned sex at birth will determine sex-specific recruitment and surveys (male vs female) employed, when needed\n* Identifies as a young professional (working 30+ hrs\u002Fweek)\n* May identify as an E-gamer (playing video games 5+hrs\u002Fweek for the past year)\n* Resides in the United States\n* Has the opportunity for at least 30% improvement in their primary health outcome\n* Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study\n\nExclusion\n\nIndividuals who report any of the following during screening may be excluded from participation:\n\n* Report being pregnant, trying to become pregnant, or breastfeeding\n* Unable to provide a valid US shipping address and mobile phone number\n* Reports current enrollment in another clinical trial\n* Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)\n* Unable to read and understand English at a 7th grade level\n* Reports a current and\u002For recent (up to 3 months ago) major illness and\u002For surgery that poses a known, significant safety risk.\n* Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and\u002For a significant safety risk with any of the study product ingredients.\n\n  * NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure\n* Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients.",{"count":398,"type":23},600,[26],"Radicle Clarity CNM™: A randomized, double-blind, placebo-controlled direct-to-consumer study assessing the impact of health and wellness products on cognitive function and related health outcomes among E-Gamers.",[30],"2026-01-28",{"date":404,"type":39},"2026-02-04",{"date":406,"type":23},"2026-02-26",{"date":408,"type":23},"2027-02-26",{"name":74,"class":46},{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":416,"eligibilityCriteria":417,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":418,"enrollmentInfo":419,"targetDuration":4,"studyType":24,"phases":421,"briefSummary":422,"conditions":423,"keywords":426,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":446},"100391175","phase-4-effect-on-body-movement-and-mental-skills-in-patients-who-received-gadolinium-based-contrast-media-for-magnetic-resonance-examination-multiple-times-within-5-years-100391175","NCT04373564","Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years","Prospective Evaluation of Potential Effects of Repeated Gadolinium-based Contrast Agent (GBCA) Administrations of the Same GBCA on Motor and Cognitive Functions in Neurologically Normal Adults in Comparison to a Non-GBCA Exposed Control Group","ODYSSEY","Inclusion Criteria:\n\n* Participant must be neurologically normal, defined as free of unstable neurologic and psychiatric disease as confirmed by a normal neurologic examination at screening\n* Participant (GBCA-exposed or controls) agrees to undergo unenhanced magnetic resonance imaging (UE-MRI) of the brain at enrollment and at the end of the observation period (5 years)\n* Participants should have at least 1 of the following indications: a) Medium to high risk for breast cancer or dense breasts undergoing breast cancer screening with MRI, b) Elevated prostate-specific antigen (PSA) and under active diagnostic surveillance for prostate cancer, c) Chronic liver disease (eg, liver cirrhosis limited to Child class A, post-hepatitis chronic hepatopathy, or primary sclerosing cholangitis) for surveillance of hepatocellular carcinoma development, d) Low-grade colorectal cancer or neuroendocrine tumor undergoing screening for liver metastases or e) Branch-duct intraductal papillary mucinous neoplasm (IPMN) of the pancreas (maximum size ≤2 cm) undergoing imaging surveillance.\n\nIn addition, for participants in the GBCA Arms only:\n\n* Each participant should be likely to undergo ≥5 GBCA-enhanced MR examinations with the same GBCA at least annually throughout the 5-year study duration\n* Prospective participants with up to 3 well documented GBCA administrations prior to study screening are acceptable, provided that the imaging was performed with the same GBCA as the one to be prospectively used in the study. If the GBCA used cannot be identified, he\u002Fshe cannot be enrolled.\n\nFor the Control Arm:\n\n* Participants who never had and are not likely to receive any GBCA injection during the course of the study\n* Each control participant must be willing to undergo UE-MRI of the brain at baseline and at Year 5. In Years 1 to 4, the control participants will undergo their clinically indicated UE-MRIs, computed tomography (CT), ultrasound, or X-ray procedures\n\nExclusion Criteria:\n\n* As evidenced by history or determined in the neurologic exam at screening, concurrent neurological and\u002For psychiatric disease (or treatments) that could influence the results of the study's motor and cognitive tests (e.g. Cerebrovascular disease, Multiple sclerosis, Neurodegenerative disease, Malignant disease other than listed in indications, Carcinoid tumors, Epilepsy, Prior neurosurgery, Psychotic disorders or any prior psychotic episode not otherwise specified - any documented prior history of chronic schizophrenia, Remittent or current medically confirmed major depressive disorder or bipolar disorder, History of long-term major depression or bipolar affective disorder with an active episode in the past 2 to 5 years, Neurodevelopmental disorders (eg, trisomy 21), Uncontrolled severe migraine, Uncontrolled or controlled anxiety or depression within 6 months before enrollment, Screening scores of ≤24 on the MMSE and\u002For ≥11 on the Hospital Anxiety and Depression Scale (HADS)).\n* Prior, planned, or ongoing chemotherapy or brain irradiation\n* Use of concomitant medication(s) affecting neuro-cognitive or motor function\n* Substance or alcohol abuse as determined by the investigator\n* Alcoholic cirrhosis\n* Renal disease, defined as estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin\u002F1.73 m2\n* History of environmental\u002Foccupational\u002Fother exposure to one or more chemicals that may affect cognitive and\u002For motor function, including, but not limited to, heavy metals (arsenic \\[As\\], cadmium \\[Cd\\], lead \\[Pb\\], manganese \\[Mn\\], and mercury \\[Hg\\]), pesticides, solvents, or carbon monoxide.\n* Clinical indications requiring \\>1 contrast enhanced magnetic resonance imaging (CE-MRI) every 6 months\n* Pregnant or nursing (lactating) women\n* Presence of any metal-containing joint implants\u002Fprostheses\n\nIn addition, for participants in either of the GBCA Arms only:\n\n\\- Receipt of a GBCA or generic prior to study entry other than the specific GBCA to be administered during the course of the study.\n\nFor participants in the Control Arm only:\n\n* Participants with any previous exposure to a GBCA.\n* Participants with any contraindication to UE-MRI examinations.","64 Years",{"count":420,"type":23},2076,[208],"This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA.\n\nThe study aims to create detailed images of the organs and tissue of the human body during x-ray, CT-scan or MRI investigations, doctors are using contrast media (a kind of dye) which can be given to patients by injection into a blood vessel or by mouth.\n\nIn this study researchers want to find out whether so called gadolinium-based contrast agents (GBCAs) have an effect on body movement and mental skills when given to participants multiple times within 5 years.\n\nThe study plans to enroll about 2076 participants suffering from a condition for which they are likely to have at least annually a MRI or another imaging examinations. Only adults up to 65 years will be considered to join this study. During the study duration of 5 years participants will receive annually a MRI or other imaging tests (such as CT-scan, x-ray) and will visit the study doctor at least 7 times for physical examinations, laboratory investigations and tests on body movement and mental skills.",[424,30,425],"Motor Function","Contrast Media",[427,428,429,430,431,432,241,433,434,435,436,437],"Motor function assessment","Cognitive function assessment","Magnetic Resonance Imaging (MRI)","Gadolinium","Gadolinium-based contrast agent (GBCA)","Gadolinium retention","Prostate cancer","Hepatocellular carcinoma","Colorectal cancer","Neuroendocrine tumor","Branch-duct intraductal papillary mucinous neoplasm (IPMN) of the pancreas","2026-01-21",{"date":286,"type":39},{"date":441,"type":39},"2021-03-24",{"date":443,"type":23},"2028-12-31",{"name":445,"class":46},"Guerbet",51,{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":17,"sex":18,"minAge":454,"maxAge":455,"enrollmentInfo":456,"targetDuration":4,"studyType":24,"phases":458,"briefSummary":459,"conditions":460,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":4},"100616944","oral-nutritional-supplementation-in-children-with-growth-concerns-100616944","NCT07312201","Oral Nutritional Supplementation in Children With Growth Concerns","Oral Nutritional Supplementation in Children With Growth Concerns: A Randomized, Controlled Single-blinded Study","Inclusion Criteria:\n\n* Child's parent(s) is of legal age of majority (18 years of age), must understand the informed consent form and other relevant study documents, and is willing and able to fulfill the requirements of the study protocol.\n* Evidence of a personally signed and dated informed consent document indicating that the child's parent(s) \u002F legally acceptable representative (LAR) has been informed of all pertinent aspects of the study.\n* Child was full-term at birth (i.e., ≥ 37 completed weeks of gestation with a birth weight of ≥ 2.5 kg and ≤ 4.5 kg).\n* Child is aged 24 - 41 months at inclusion.\n* Child is generally healthy (acute illnesses in a minor condition which are common in childhood such as viral or bacterial infections (e.g., conjunctivitis, otitis media, upper\u002Flower respiratory tract infection, gastroenteritis, hand foot \\& mouth disease) at time of enrolment is permitted).\n* Children whose parents, caregivers, or guardians show some concern about their child's dietary intakes and growth, such as child is too thin for his or her height, or child has experienced recent rapid weight loss or failure to gain weight or height and child has a z-score for weight-for-age or weight-for-height or both parameters ≤ -1SD as per WHO growth charts.\n* Child's parents agree to feed their child an oral nutritional supplement in addition to normal diet.\n* Child's parent(s) \u002F guardian can be contacted directly by telephone throughout the study.\n\nExclusion Criteria:\n\n* Child is currently breastfed or is consuming breast milk.\n* Child is currently consuming or consumed in the past month growing-up milk \u002F toddler formula. Growing-up milks \u002F toddler formulas are products specifically formulated for young children and provide key macro- and micro-nutrients.\n* Child is currently consuming or consumed in the past month oral nutrition supplement (ONS). The standard ONS formula has an energy density of at least 0.85 kcal\u002FmL, containing protein, carbohydrate and\u002For fat, as well as a wide range of micronutrients to supplement or use as the sole source of nutrition.\n* Child has known or suspected cows' milk protein intolerance \u002F allergy, lactose intolerance, galactosemia, soy intolerance \u002F allergy, fish oil intolerance \u002F allergy, or allergy or intolerance to any ingredient in the study product.\n* Child fed vegan, vegetarian, or vegetarian plus fish diets in which milk products are excluded.\n* Underlying medical illness that could affect growth or feeding, such as gastrointestinal \\[GI\\] disorders (such as celiac disease, short bowel syndrome, maldigestion\u002Fmalabsorption, significant GI malformations or surgery etc.); neurodevelopmental disability; chronic infections (such as tuberculosis or HIV infection); congenital disease or genetic disorders (such as congenital cardiac disease, Down syndrome, thalassemia); or other chronic illness that may impact growth or feeding according to the clinician opinion.\n* Child is unable to consume foods or ONS orally (e.g. dysphagia, anorexia, difficulty in swallowing due to acquired or congenital abnormalities that would hamper oral intake of the study product.)\n* Clinically significant nutritional deficiency requiring specific nutritional therapy other than the study product (for example tube feeding)\n* Child has acute illness including acute viral infection, respiratory tract infection etc. even in a minor condition at time of enrolment. A child presenting with an acute illness can be re-screened at least two weeks after the episode of illness has resolved.\n* Child has a z-score for weight-for-height or weight-for-age or height-for-age or any combination of these three parameters ≤ -3SD as per WHO growth charts.\n* Children currently receiving or having received prior to enrolment medication which are known to impact growth including systemic steroids, growth hormone and insulin\n* Child or child's parent(s) not willing and\u002For not able to comply with scheduled visits and\u002For have plans to relocate to a different geographical location from the study location during the study period.\n* Child of any investigational site staff member or Nestlé employee directly involved in the conduct of the trial.\n* Child is currently participating in or has participated in another clinical trial within 4 weeks prior to enrolment.","24 Months","41 Months",{"count":457,"type":23},216,[26],"Multi-center, single-blinded, randomized, controlled study consisting of two arms, to investigate the impact of an oral nutritional supplement in combination with dietary counseling on growth in children with growth concerns as compared to children who receive dietary counselling alone",[461,462,463,30],"Growth","Toddlers","Attention","2025-12-16",{"date":466,"type":39},"2025-12-31",{"date":468,"type":23},"2026-09-30",{"date":470,"type":23},"2028-05-31",{"name":472,"class":46},"Société des Produits Nestlé (SPN)",{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":479,"eligibilityCriteria":480,"healthyVolunteers":17,"sex":18,"minAge":180,"maxAge":4,"enrollmentInfo":481,"targetDuration":4,"studyType":24,"phases":483,"briefSummary":484,"conditions":485,"keywords":487,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":493,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":75},"100616962","b-vitamins-and-omega-3-fatty-acids-and-biomarkers-of-brain-atrophy-100616962","NCT07312435","B-vitamins and Omega-3 Fatty Acids and Biomarkers of Brain Atrophy.","B-vitamins and ω-3 Fatty Acids to Modulate Brain Ageing in European Citizens Through Improved Nutrition: the BOOMERANG Project","BOOMERANG","Inclusion Criteria:\n\n* Age \\> 65 years\n* A low baseline B-vitamin status as assessed by plasma tHcy \\> 11 μmol\u002FL\n* Normal MMSE score (\\>25)\n\nExclusion Criteria:\n\n* Unable to give informed consent\n* Fatty fish intake \\> 2 times per week\n* daily omega-3 supplementation\n* daily B-vitamin supplementation\n* history of B12-injections\n* Serum creatinine \\> 90 μmol\u002FL for women and \\> 105 μmol\u002FL for men (above reference values)\n* aspirin use\n* renal disease\n* active cancer\n* Participants can be included if they accept to not take omega-3 supplementation or B-vitamin supplements during the study. They should stop using it and wait 12 weeks before they are invited to a screening visit.",{"count":482,"type":23},96,[26],"A poor nutrition status is a modifiable risk factor for cognitive decline and dementia. In particular, evidence links low status of certain B-vitamins and ω-3 fatty acids (ω-3 FA) with a greater risk of cognitive decline and dementia. Although these dietary components are typically investigated separately, post-hoc analyses of existing clinical trial data and experimental work indicate that B-vitamins and ω-3 FA may exert synergistic beneficial effects on processes related to brain health and cognition. However, this combination has not been tested directly in humans. In the proposed BOOMERANG project, we will study the effects of jointly supplementing with B-vitamins and a highly bioavailable ω-3 FA supplement, Lysoveta, on a robust biomarker of brain atrophy, the neurofilament light chain, in a double-blinded randomized controlled trial (RCT) over 3 months in older adults. We will also examine the secondary effects of the supplement of quality of life and cognitive function.",[486,30],"Dementia",[488,489,490,491,492],"Nutrition","Omega3","B vitamins","older adults","cognition",{"date":466,"type":39},{"date":495,"type":39},"2025-09-01",{"date":497,"type":23},"2028-06-01",{"name":499,"class":106},"University of Oslo",{"id":501,"slug":502,"hasResults":12,"nctId":503,"briefTitle":504,"officialTitle":504,"acronym":505,"eligibilityCriteria":506,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":507,"enrollmentInfo":508,"targetDuration":4,"studyType":24,"phases":510,"briefSummary":511,"conditions":512,"keywords":517,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":527,"lastUpdatePostDateStruct":528,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":534,"locationsCount":75},"100567804","dose-response-impact-of-glucosyl-hesperidin-citrapeak-on-exercise-performance-blood-flow-stress-cognition-and-other-perceptual-indicators-100567804","NCT06672952","Dose-Response Impact of Glucosyl-Hesperidin (CitraPeak) on Exercise Performance, Blood Flow, Stress, Cognition, and Other Perceptual Indicators","HES","Inclusion Criteria:\n\n1. Participants who are between 18 - 50 years of age\n2. Body mass index values will range from \\>25.0 \\\u003C 30.0 kg\u002Fm2\n3. The average body mass index for entire study cohort will be less than 27.0 kg\u002Fm2. As such an ongoing calculation of the recruited cohort's mean body mass index will be maintained and people will only be randomized into the study if the average cohort body mass index value does not exceed 27.0 kg\u002Fm2\n4. Free-living and independent\n5. In good health absent of being overweight or mildly obese with no other signs or symptoms of cardiovascular, respiratory, metabolic, immune, psychiatric, or musculoskeletal disease or disorders\n6. Willingness to maintain consistent sleep duration the evening before study visits\n7. Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, and carry out all study-related procedures\n8. Regular completion of at least 180 minutes of moderate to vigorous exercise per week for the past 6 months\n\nExclusion Criteria:\n\n1. Not currently completing at least 180 minutes of moderate to vigorous exercise per week for the past 6 months\n2. Positive medical history and\u002For is currently being treated for some form of heart disease, cardiovascular disease\n3. Currently being treated for kidney disease, renal failure, or has dialysis performed on regular intervals\n4. Has liver disease or some form of clinically diagnosed hepatic impairment\n5. Diagnosed with having Type I or Type II diabetes (determined as fasting blood glucose \\> 126 mg\u002FdL)\n6. Diagnosed with or is being treated for some form of thyroid disease\n7. Diagnosed with major affective disorder or other psychiatric disorder that required hospitalization in the prior year\n8. Diagnosed with some form of immune disorder (i.e., HIV\u002FAIDS)\n9. History of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit).\n10. Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea)\n11. Positive medical history for any neurological condition or neurological disease\n12. Currently prescribed a statin drugs (i.e., Lipitor, Livalo, Crestor, Zocor, etc.) or any hypertension medications (i.e., Beta-blockers, ACE Inhibitors, Alpha blockers, Vasodilators, etc.)\n13. Current smoker (average of \\> 1 pack per day within the past 3 months) has quit within the past six months. This includes all forms of nicotine\n14. Intake of any drugs (prescribed or over the counter) or dietary supplements that are known or are purported to weight loss such as thermogenics, hydroxycitric acid, ephedra, capsaicin, etc.\n15. Participants who are lactating, pregnant or planning to become pregnant\n16. Have a known sensitivity or allergy to any of the study products\n17. History of alcohol or substance abuse in the 12 months prior to screening\n18. Receipt or use of an investigational product in another research study within 30 days of beginning the study protocol\n19. Any orthopedic limitation that would prevent participation in a general fitness program\n20. Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data","50 Years",{"count":509,"type":23},60,[26],"The purpose of this study is to evaluate the dose-dependent effects of glucosyl-hesperidin (CITRAPEAK) supplementation on exercise performance, recovery indicators, blood flow, cognitive function, mood, sleep, and fuel utilization in recreationally active adults.",[123,513,30,514,515,516],"Exercise Recovery","Nitric Oxide","Blood Flow","Endurance Exercise",[518,519,520,521,522,33,523,524,525,526],"exercise performance","aerobic capacity","anaerobic power","mood","nitric oxide","glucosyl-hesperidin","training readiness","fuel utilization","endothelial function","2025-12-05",{"date":529,"type":39},"2025-12-12",{"date":531,"type":39},"2025-04-15",{"date":533,"type":23},"2026-01-01",{"name":535,"class":106},"Lindenwood University",{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":540,"acronym":541,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":84,"minAge":278,"maxAge":543,"enrollmentInfo":544,"targetDuration":4,"studyType":24,"phases":546,"briefSummary":547,"conditions":548,"keywords":551,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":558,"leadSponsor":560,"locationsCount":75},"100612888","time-restricted-eating-in-survivors-trial-20-100612888","NCT07259434","Time Restricted Eating in Survivors Trial 2.0","TEST2","Inclusion Criteria:\n\n* female\n* aged 60-85 years\n* BMI ≥25 kg\u002Fm2\n* diagnosed with early-stage (I-III) BC in the past 15 years\n* received chemotherapy treatment that was completed ≥1 year earlier\n* Montreal Cognitive Assessment (MoCA) score of 10-30 which aligns with no impairment to moderate impairment thresholds.\n\nExclusion Criteria:\n\n* does not have a mobile device that connects to Bluetooth and can send\u002Freceive text messages\n* history of physician-diagnosed heart disease, dementia or Alzheimer's disease, diabetes that requires insulin or sulfonylurea usage, or eating disorder\n* MoCA total score \\\u003C10 (indicating dementia)\n* ≥5kg weight change within past 3 months\n* taking lipid- or weight-lowering medication (e.g. statins or GLP-1 agonists)\n* high-risk for malnutrition (≥3 on the Malnutrition Screening Tool)\n* research MRI contraindications (e.g., pacemaker, breast tissue expander, magnetic implants)\n* eating all daily calories in \\\u003C10h\u002Fd in the past 3 months\n* following a structured dietary practice (e.g., ketogenic diet, Weight Watchers) or actively trying to lose weight in the past 3 months\n* being unable to make adjustments to eating time or nutrient intake\n* regularly doing \\>90 min\u002Fweek of moderate physical activity in the past 3 months\n* severe claustrophobia\n* BMI\\>40 kg\u002Fm2 (due to body habitus fit within MRI scanner bore)\n* major psychiatric disorders (e.g. bipolar, post-traumatic stress disorder, schizophrenia)\n* neurological disorders that significantly impact physical or cognitive function (epilepsy, stroke, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, muscular dystrophy) or traumatic brain injury resulting in ongoing neurological deficits. If the screening process identifies patients with undiagnosed severe cognitive function (MoCA score \\\u003C10) or at high risk for malnutrition (≥3 on the Malnutrition Screening Tool), the investigators will recommend that the individual see their family physician. In this process, the investigators will ask the participant if there is a family member that can also receive this information.","85 Years",{"count":545,"type":23},152,[26],"After chemotherapy, older breast cancer survivors experience a faster decline in brain function. This can make it harder to enjoy life, stay social, and maintain independence. Chemotherapy can lead to poorer lifestyle habits, like unhealthy eating, less exercise, high stress, and poor sleep. Chemotherapy can also affect important health markers like blood sugar and cholesterol. Over time, these changes can damage blood vessels, which might lead to heart and brain issues. The investigators do not fully understand why brain function declines faster after chemotherapy, especially in older survivors, because there are many factors involved. In this study, the investigators will look at how lifestyle habits (like diet, exercise, stress and sleep), health markers (like blood sugar and cholesterol), and blood vessel health (like how well blood flows and how stiff the blood vessels are) affect brain function in older breast cancer survivors. The investigators will include 152 females aged 60-85 years, who finished chemotherapy for early-stage breast cancer at least 1 year ago. The investigators will use special tests to check different parts of brain function, like language, memory, and attention, as well as brain blood vessel health. This will help to understand which factors might speed up or slow down memory and thinking problems. Since many Canadian breast cancer survivors experience faster decline in brain function after chemotherapy, this study aims to find out what might make it worse. The results could help to create better and more personalized treatment plans for older breast cancer survivors that protect brain health and reduce problems with brain function in the future.",[549,550,30,330],"Breast Cancer","Cardiovascular Risk",[552,553],"Treatment","Prevention","2025-11-20",{"date":556,"type":39},"2025-12-02",{"date":533,"type":23},{"date":559,"type":23},"2028-10-31",{"name":561,"class":106},"University of Toronto",{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":17,"sex":18,"minAge":180,"maxAge":569,"enrollmentInfo":570,"targetDuration":4,"studyType":24,"phases":572,"briefSummary":573,"conditions":574,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":576,"startDateStruct":578,"completionDateStruct":580,"leadSponsor":582,"locationsCount":4},"100612234","exploring-the-effectiveness-of-somatosensory-cognitive-game-intervention-on-cognitive-and-physical-functions-100612234","NCT07250932","Exploring the Effectiveness of Somatosensory Cognitive Game Intervention on Cognitive and Physical Functions","Exploring the Effectiveness of Somatosensory Cognitive Game Intervention on Cognitive and Physical Functions in Older Adults","Inclusion Criteria:\n\n1. Elderly individuals aged 65 and above.\n2. Able to communicate in Chinese (Mandarin or Taiwanese).\n3. Voluntarily participate in this study and sign a written consent form.\n\nExclusion Criteria:\n\n1. Individuals with severe visual impairments or physical mobility disabilities that prevent them from participating in the game activities designed in this study.\n2. Individuals diagnosed with severe dementia who are unable to understand or participate in the research process.","100 Years",{"count":571,"type":23},80,[26],"This study investigates the effects of somatosensory cognitive games interventions on older adults' cognitive and physical functions. The investigators plan to recruit up to 100 participants and randomly assign them to a control group or an experimental group. The experimental group will participate in somatosensory cognitive games for 12 weeks, while the control group will receive routine care. Data will be collected via questionnaires to examine whether somatosensory cognitive games can delay declines in cognitive and physical functions in older adults.",[30],"2025-11-18",{"date":577,"type":39},"2025-11-26",{"date":579,"type":23},"2025-11",{"date":581,"type":23},"2027-12",{"name":583,"class":106},"Taipei Medical University",{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":590,"eligibilityCriteria":591,"healthyVolunteers":12,"sex":84,"minAge":235,"maxAge":4,"enrollmentInfo":592,"targetDuration":4,"studyType":183,"phases":4,"briefSummary":594,"conditions":595,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":600,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":606,"locationsCount":609},"100583420","sarcopenia-in-gestational-diabetes-100583420","NCT06876090","Sarcopenia in Gestational Diabetes","Sarcopenia in Gestational Diabetes: The SiGnal-D Study","SiGnal-D","Inclusion Criteria:\n\nAt least one among the following conditions:\n\n* Age equal to or higher than 35 years;\n* Body mass index (BMI) equal to or higher than 25 kg\u002Fm\\^2;\n* Glycemia between 5.6 and 6.9 mmol\u002FL before or at the beginning of pregnancy;\n* Fetal macrosomia in previous pregnancy;\n* GDM in previous pregnancy;\n* First-degree family history of diabetes.\n\nExclusion Criteria:\n\n* Unmatching of at least one among the inclusion criteria;\n* Twin pregnancy;\n* Presence of any already known disease\u002Fdisorder possibly affecting muscle mass or function;\n* Neurological or psychiatric diseases;\n* Already known diabetes (e.g., type 1 or type 2 diabetes).",{"count":593,"type":23},200,"Sarcopenia is a syndrome characterized by loss of skeletal muscle mass and strength, and physical performance deterioration. Prevalence of sarcopenia in elderly people is remarkably high (prevalence of about 25% in 60+ years people). In type 2 diabetes (T2D), sarcopenia is emerging as comorbidity of major concern. Sarcopenia, however, is not limited to elderly people, as it can develop also in younger individuals with prevalence around 9% or even higher according to some investigators. Of note, sarcopenia has been reported even in the 20-29 years interval. This interval includes women of childbearing age, thus raising the question whether sarcopenia may occur also in women with gestational diabetes (GDM) and whether this may affect pregnancy outcomes. Also, association between sarcopenia and cognitive impairment has been repeatedly reported, to the point that some authors have emphasized the importance of early sarcopenia recognition for prevention of cognitive impairment. Therefore, our main aims are:\n\n1. To ascertain whether sarcopenia is present in GDM and, in that case, its prevalence;\n2. To identify risk factors for sarcopenia;\n3. To determine sarcopenia impact on pregnancy outcomes, and cognitive function.\n\nDuring pregnancy, all women will undergo oral glucose tolerance test (OGTT) for assessment of the glucometabolic condition. Several clinical variables of interest in sarcopenia will also be recorded. As regards the OGTT data, special focus will be on the assessment of insulin resistance, both at fasting and during the dynamic conditions determined by the OGTT. Notably, the special interest for insulin resistance is due to the reason that this type of metabolic alteration is known to be a risk factor for sarcopenia. In fact, all women will then undergo testing for diagnosis of sarcopenia (or presarcopenia), and all data and parameters will be analyzed to identify relationships between sarcopenia-related variables and GDM-related ones. It is worth noting that in consideration of the exacerbated insulin resistance condition often observed in GDM, the investigators expect indeed a not negligible prevalence of sarcopenia (or at least presarcopenia) in GDM women, despite the young (non-elderly) age. In addition, since insulin resistance is often present in pregnancy even in the absence of dysglycemia, the investigators do not exclude to identify some cases of sarcopenia\u002Fpresarcopenia even in pregnant non-GDM women. This study will be the basis for future studies (also of interventional type), especially in women with GDM for prevention of sarcopenia and related possible pregnancy complication and adverse pregnancy outcomes, as well as for possibly contributing to mitigation of risk for T2D development in later life.",[596,597,598,599,30],"Sarcopenia","Gestational Diabetes Mellitus (GDM)","Pregnancy Complications","Adverse Maternal and Neonatal Outcomes",{"date":601,"type":39},"2025-11-21",{"date":603,"type":39},"2025-05-28",{"date":605,"type":23},"2026-04",{"name":607,"class":608},"Istituto di Neuroscienze Consiglio Nazionale delle Ricerche","NETWORK",3,{"id":611,"slug":612,"hasResults":12,"nctId":613,"briefTitle":614,"officialTitle":614,"acronym":4,"eligibilityCriteria":615,"healthyVolunteers":17,"sex":616,"minAge":617,"maxAge":618,"enrollmentInfo":619,"targetDuration":4,"studyType":24,"phases":620,"briefSummary":621,"conditions":622,"keywords":626,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":630,"startDateStruct":632,"completionDateStruct":634,"leadSponsor":636,"locationsCount":4},"100605911","the-effects-of-visual-input-on-cognitive-function-physical-performance-and-postural-stability-in-adolescent-male-basketball-players-100605911","NCT07168681","The Effects of Visual Input on Cognitive Function, Physical Performance, and Postural Stability in Adolescent Male Basketball Players","Inclusion Criteria:\n\n* Male basketball players aged 14-19 years\n* With at least one year of basketball experience\n* Minimum training frequency of two days per week.\n\nExclusion Criteria:\n\n* Not willing to participate in the study\n* A history of any upper or lower extremity surgery within the past year\n* A history of any musculoskeletal injury in the upper or lower extremities within the past month\n* The presence of a neurological disorder\n* A history of epilepsy\n* A diagnosis of attention deficit hyperactivity disorder (ADHD)","MALE","14 Years","19 Years",{"count":5,"type":23},[26],"The aim of this study is to investigate the effects of exercises performed with stroboscopic glasses-recently gaining popularity in sports-on cognitive function, physical performance, and postural stability, which are among the key skills in athletic performance.\n\nThe originality of the study lies in being the first to examine the effects of stroboscopic glasses-based exercises on basketball players.\n\nHypotheses of the study:\n\nH1: Exercises performed with stroboscopic glasses have an effect on athletes' cognitive functions.\n\nH2: Exercises performed with stroboscopic glasses have an effect on athletes' physical performance.\n\nH3: Exercises performed with stroboscopic glasses have an effect on athletes' static and dynamic postural stability.",[623,624,30,130,625],"Sports Physical Therapy","Stroboscopic Visual Training","Postural Stability",[627,628,33],"physical performance","stroboscopic visual training","2025-09-04",{"date":631,"type":39},"2025-09-11",{"date":633,"type":23},"2025-09-15",{"date":635,"type":23},"2027-10-30",{"name":637,"class":106},"Hacettepe University",{"id":639,"slug":640,"hasResults":12,"nctId":641,"briefTitle":642,"officialTitle":642,"acronym":643,"eligibilityCriteria":644,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":645,"targetDuration":4,"studyType":24,"phases":646,"briefSummary":647,"conditions":648,"keywords":652,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":656,"lastUpdatePostDateStruct":657,"startDateStruct":659,"completionDateStruct":661,"leadSponsor":663,"locationsCount":75},"100412627","multi-level-approach-of-brain-activity-using-intracranial-electrodes-in-epileptic-patients-100412627","NCT04653012","Multi-level Approach of Brain Activity Using Intracranial Electrodes in Epileptic Patients","EpiMicro","Inclusion Criteria:\n\n* Patients with focal drug-resistant epilepsy\n* Patients who undergo a presurgical evaluation with intracranial electrodes in the videoEEG unit of the Neurology department at the Pitié-Salpêtrière hospital.\n* Patients who have been informed and provided written informed consent to take part in the study\n\nExclusion Criteria:\n\n* Contraindication for an intracranial investigation (with macro-electrodes) : intercurrent infectious syndrome, decompensated associated pathology (cardiac, pulmonary, renal, hepatic), patient with increased risk of infection (ex: under immunosuppressive therapy)\n* Pregnant or parturient woman\n* Breastfeeding woman\n* Minor person or legally protected adult (tutelage, legal guardianship, maintenance of justice)",{"count":182,"type":23},[26],"The main goal of this project is to study the mechanisms of epileptic activities using intracranial macro and micro electrodes in epileptic patients undergoing pre-surgical investigation.\n\nThe recordings will also be used to study physiological mechanisms like sleep and different cognitive functions.",[649,650,30,651],"Focal Epilepsy","Electrodes, Implanted","Neurophysiology",[653,654,655],"Microelectrodes","Seizures","EEG","2025-09-02",{"date":658,"type":39},"2025-09-08",{"date":660,"type":39},"2021-02-28",{"date":662,"type":23},"2031-02-27",{"name":664,"class":665},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",{"id":667,"slug":668,"hasResults":12,"nctId":669,"briefTitle":670,"officialTitle":671,"acronym":4,"eligibilityCriteria":672,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":673,"enrollmentInfo":674,"targetDuration":4,"studyType":24,"phases":675,"briefSummary":676,"conditions":677,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":682,"lastUpdatePostDateStruct":683,"startDateStruct":685,"completionDateStruct":687,"leadSponsor":689,"locationsCount":75},"100541531","square-step-exercises-in-healthy-young-adults-100541531","NCT06331078","Square Step Exercises in Healthy Young Adults","Comparison of the Effects of Square Step Exercises and Aerobic Exercise on Cognitive Functions and Physical Fitness in Healthy Young Adults","Inclusion Criteria:\n\n* International Physical Activity Questionnaire score \\\u003C600 Metabolic Equivalents (METs),\n* No neurological or orthopedic problems affecting gait, balance and lower extremities\n* No vision or hearing problems, and no history of musculoskeletal surgery.\n\nExclusion Criteria:\n\n* Participants who have pain due to a musculoskeletal problem\n* Participants who are continuing another routine exercise program","30 Years",{"count":182,"type":23},[26],"This study aims to compare the effectiveness of Square Stepping Exercise and aerobic exercise on cognitive function and physical fitness in young adults. Participants aged 18-30 with low physical activity levels will be randomly assigned to either the Square Stepping Exercise Group or Aerobic Exercise Group. Both interventions will be supervised by a physiotherapist, performed twice a week for 40 minutes over 4 weeks. Cognitive function will be assessed using various tests, including attention, short-term memory, and executive function evaluations. Physical fitness will be evaluated through jump tests and balance assessments. Blinded assessors will conduct evaluations at baseline and post-intervention in both groups to determine the impact of square stepping exercise and aerobic exercise on cognitive and physical health in young adults.",[678,679,680,30,681],"Exercise","Square Step Exercises","Aerobic Exercise","Physical Fitness","2025-08-14",{"date":684,"type":39},"2025-08-19",{"date":686,"type":23},"2025-12-01",{"date":688,"type":23},"2027-12-01",{"name":690,"class":106},"Fenerbahce University"]